title: Evolving pharmacotherapies for the treatment of metastatic melanoma.
abstract: Metastatic melanoma remains a difficult disease to treat, and long term survivors are rare. Over the past few years, however, breakthroughs in both immunotherapy as well as targeted agents have had a tremendous impact on patients diagnosed with this disease. This review summarizes recent advances in systemic therapies for melanoma, including immune modulators directed against cytotoxic T lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), as well as a number of targeted agents. These approaches hold great promise as the landscape of therapeutic options for advanced melanoma continues to evolve.
authors.affiliation: Division of Medical Oncology, Duke University Medical Center, Durham NC, USA.
authors.forename: April K S
authors.initials: AK
authors.lastname: Salama
keywords: BRAF; KIT; MEK; PD-1; ipilimumab; metastatic melanoma; therapy